Search

Methylene blue

clinical trials to be an inhibitor of Tau protein aggregation. … Its use as an urinary tract antiseptic has also been investigated.

Mitapivat

[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells.

Dornase alfa

Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. … In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.

Eugenol

Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. … It has been used as a topical antiseptic as a counter-irritant and in dental preparations with zinc oxide for root canal sealing and pain control.

Debrisoquine

An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

Isosulfan blue

Efgartigimod alfa

Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … and a reduction in electrical nerve impulses.

Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

Fluticasone furoate

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].

Amivantamab

[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … [L41469] On December 17, 2025, the U.S.